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We noted this study by Dovell *et al.* [@bib1] comparing post-endovascular aneurysm repair (EVAR) outcomes in the context of whether regional (RA) or general anaesthesia (GA) had been used, based on the convenient and robust UK National Vascular Registry (NVR). As indicated, the way anaesthetic details are captured in the NVR is not entirely accurate: RA could imply any of a plethora of options ranging from combined spinal epidural anaesthesia, single shot spinal anaesthesia, and as indicated, use of local anaesthesia infiltration may well be confounded by supplementary use of opioid analgesia.

Our own approach has evolved to peri-arterially infiltrating a mixture of 1% lidocaine (10 mL) and 0.25% [l]{.smallcaps}-bupivacaine (20 mL) under ultrasound guidance, with an intravenous bolus of midazolam (1--3 mg) and a target controlled infusion of remifentanil (1.0--2.5 ng/mL, plasma) for percutaneous infrarenal EVAR (median length of stay (LOS) 1 day, 2015--2020); this allows verbal contact with the patient, including breath holding for aorto-iliac angiography, as well as reducing the monitoring requirements associated with spinal anaesthesia. Such protocols can be applied to a day case EVAR programme.

Regardless of the results in the rupture scenario favouring RA, and the ill-received NICE guidelines tending towards open repair and thus a default GA, there may be another lingering factor that will drive the need for both local/regional anaesthesia and EVAR, and that is the COVID-19 pandemic. This correlates with the need to reduce aerosol generating procedures, namely endotracheal intubation, intensive care unit stay, and respiratory complications including, of concern (perhaps even leading to patient refusal to have a GA) the risk of hospital acquired SARS-CoV-2 infection.

A repeat audit going forward to look for any post-pandemic changes in EVAR anaesthetic practice may therefore be useful.
